uniQure (NASDAQ: QURE) is one of the biotech stocks to buy according to Wall Street analysts. Earlier on June 2, uniQure provided a regulatory update on AMT-130, which is the company’s investigational ...

The consensus price target hints at a 142.7% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...